2024年6月最新影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | Targeted Oncology TARGET ONCOL （此期刊被最新的JCR期刊SCIE收录） LetPub评分 7.3
50人评分
我要评分
声誉 8.8 影响力 6.1 速度 7.0 | |||||||||||||||||||||||||
| 期刊ISSN | 1776-2596 | 微信扫码收藏此期刊 | ||||||||||||||||||||||||
| E-ISSN | 1776-260X | |||||||||||||||||||||||||
| 2023-2024最新影响因子 （数据来源于搜索引擎） | 4.4 点击查看影响因子趋势图 | |||||||||||||||||||||||||
| 实时影响因子 | 截止2024年10月29日：2.877 | |||||||||||||||||||||||||
| 2023-2024自引率 | 2.30%点击查看自引率趋势图 | |||||||||||||||||||||||||
| 五年影响因子 | 3.9 | |||||||||||||||||||||||||
| JCI期刊引文指标 | 0.85 | |||||||||||||||||||||||||
| h-index | 35 | |||||||||||||||||||||||||
| CiteScore （ 2024年最新版） |
| |||||||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||||||
| 期刊官方网站 | https://www.springer.com/11523 | |||||||||||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/targ | |||||||||||||||||||||||||
| 作者指南网址 | https://www.springer.com/11523/submission-guidelines | |||||||||||||||||||||||||
| 期刊语言要求 | Language Presenting your work in a well-structured manuscript and in well-written English gives it its best chance for editors and reviewers to understand it and evaluate it fairly. Many researchers find that getting some independent support helps them present their results in the best possible light. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足Targeted Oncology的语言要求，还能让Targeted Oncology编辑和审稿人得到更好的审稿体验，让稿件最大限度地被Targeted Oncology编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||||||
| 通讯方式 | SPRINGER, VAN GODEWIJCKSTRAAT 30, DORDRECHT, NETHERLANDS, 3311 GZ | |||||||||||||||||||||||||
| 出版商 | Springer International Publishing | |||||||||||||||||||||||||
| 涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||||||
| 出版国家或地区 | FRANCE | |||||||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||||||
| 出版周期 | Quarterly | |||||||||||||||||||||||||
| 出版年份 | 2006 | |||||||||||||||||||||||||
| 年文章数 | 70点击查看年文章数趋势图 | |||||||||||||||||||||||||
| Gold OA文章占比 | 51.26% | |||||||||||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 75.71% | |||||||||||||||||||||||||
| WOS期刊SCI分区 （ 2023-2024年最新版） | WOS分区等级：2区
| |||||||||||||||||||||||||
| 中国科学院《国际期刊预警 名单（试行）》名单 | 2024年02月发布的2024版：不在预警名单中 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2020年12月发布的2020版：不在预警名单中 | |||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2023年12月最新升级版） | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2022年12月升级版） |
| |||||||||||||||||||||||||
| 中国科学院SCI期刊分区 （ 2021年12月旧的升级版） |
| |||||||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1776-2596%5BISSN%5D | |||||||||||||||||||||||||
| 平均审稿速度 | 网友分享经验： >12周，或约稿 | |||||||||||||||||||||||||
| 平均录用比例 | 网友分享经验： 较易 | |||||||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在Targeted Oncology顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies Author: Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B.; Ramalingam, Suresh S.; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; Yang, James Chih-Hsin Journal: TARGETED ONCOLOGY. 2023; Vol. 18, Issue 1, pp. 9-24. DOI: 10.1007/s11523-022-00941-7 PubMed DOI |
| 2. | Distribution of <Emphasis Type="Italic">ALK</Emphasis> Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib Author: Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00631-x DOI |
| 3. | Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study Author: Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00630-y DOI |
| 4. | Clinical Management of Non-Small Cell Lung Cancer with Concomitant <Emphasis Type="Italic">EGFR</Emphasis> Mutations and <Emphasis Type="Italic">ALK</Emphasis> Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib Author: Yiming Zhao, Shuyuan Wang, Bo Zhang, Rong Qiao, Jianlin Xu, Lele Zhang, Yanwei Zhang, Baohui Han Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00628-6 DOI |
| 5. | Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors Author: Xiang Chen, JiaXi Yao, Li Liu, WenZhong Zheng, XiaoYi Hu, YanJun Zhu, Hang Wang, JianMing Guo Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00625-9 DOI |
| 6. | Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy Author: Zhuanglin Li, Mingxue Wang, Xuejing Yao, Wenting Luo, Yaocheng Qu, Deling Yu, Xue Li, Jianmin Fang, Changjiang Huang Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-018-0616-8 DOI |
| 7. | Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy Author: Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui Journal: Targeted Oncology, 2018, Vol.13, 757-767, DOI:10.1007/s11523-018-0602-1 DOI |
| 8. | Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis Author: Gaofeng Pan, Shaobo Ke, Jinping Zhao Journal: Targeted Oncology, 2013, Vol.8, 107-116, DOI:10.1007/s11523-013-0272-y DOI |
| 9. | Hyperbaric oxygen and cancer: more complex than we expected Author: Liu Wenwu, Sun Xuejun, Tao Hengyi, Liu Kan Journal: Targeted Oncology, 2013, Vol.8, 79-81, DOI:10.1007/s11523-013-0259-8 DOI |
| 10. | Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis Author: Xue Li, Minghuan Li, Zhen Lian, Hui Zhu, Li Kong, Ping Wang, Jinming Yu Journal: Targeted Oncology, 2016, Vol.11, 753-761, DOI:10.1007/s11523-016-0451-8 DOI |
|
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2024 中国: LetPub上海 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
增值电信业务经营许可证：沪B2-20211595 网络文化经营许可证：沪网文[2023]2004-152号
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦1803室
安全保密
